

Thursday 30 March

1400 - 1530

Hall A

The Philosophy Of Drug Development

Chair Roger Vogel

005/ OR1

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 INTRODUCTION: THE ISSUES FOR THE PATIENT, THE PHYSICIAN, THE REGULATORS AND THE PHARMACEUTICAL INDUSTRY R.Vogel, USA (*)		9020.00	9982
1415	0 QUANTIFICATION OF VISUAL FUNCTION AND VISUAL CHANGE - INSTRUMENTS AND MEASURES M.Verdugo, USA (*)		9021.00	9954
1430	0 VALUE BASED MEDICINE - THE NEW PARADIGM M.Brown (*)		9022.00	10828
1445	0 THE REQUIREMENT FOR EFFICACY IN ASSESSMENT OF DRUGS FOR SIGN THREATENING DISEASES W.Chambers, USA (*)		9024.00	4009
1500	0 WHO DECIDES THE AVAILABILITY OF CARE? J.Bottomley (*)		9025.00	10829
1515	0 DRUG DEVELOPMENT - A MULTI PARAMETRIC EQUATION R.Neumann, Israel (*)		9026.00	8555
1530	0 COFFEE BREAK		9001.00	10618

1400 - 1445

Hall B

Ocular Blood Flow In Eye Disease

Chair Alon Harris

010/ OR2

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 THE IMPORTANCE OF OCULAR BLOOD FLOW IN MACULAR DEGENERATION A.Harris, USA (*)		1159.00	6650
1415	0 THE EFFECTS OF MEDICATION ON OCULAR BLOOD FLOW M.Lesk, Canada (*)		9040.00	10628
1430	0 THE IMPORTANCE OF OCULAR BLOOD FLOW IN GLAUCOMA P.Netland, USA (*)		1227.00	11128

1445 - 1530

Hall B

Allergy

Chair Michael B. Raizman

020/ OR3

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	0 TREATMENT OF SCAR FORMING CONJUNCTIVITIS N.Barney, USA (*) ; E.Cook, USA ; J.Stahl, USA ; F.Graziano, USA		1163.00	3128
1455	0 THE NEW GENERATION OF ANTIALLERGIC EYE DROPS S.Bonini, Italy (*)		9043.00	3286
1505	0 ASSESSMENT OF MAST CELL STABILIZATION IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS A.Leonardi, Italy (*)		1073.00	7691

Thursday 30 March

1445 - 1530

Hall B

Allergy

Chair Michael B. Raizman

020/ OR3

Time	Title	Poster Board Number	Abstract Number	Reference I
1515	0 THE EFFECTS OF ANTI-ALLERGIC DRUGS ON OCULAR CYTOKINE RESPONSES V.Calder, UK (*) ; Y.Ajayi ; G.Galatowicz		1215.00	3933
1525	0 DISCUSSION		9045.00	10618
1530	0 COFFEE BREAK		9002.00	10618

1600 - 1645

Hall A

European Drug Development

Chair Jose Cunha-Vaz

025/ OR4

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 A EUROPEAN NETWORK OF CERTIFIED CLINICAL TRIALS CENTRES OF OPHTHALMOLOGY - EVI.CT.SE J.Cunha-Vaz, Portugal (*)		1120.00	10375
1610	0 THE ISSUE OF PRESERVATIVE EFFICACY TESTING REQUIREMENTS IN THE DEVELOPMENT OF OPHTHALMIC DRUGS IN EUROPE K.Geldsetzer (*) ; B.Matthews ; F.Skinner		1126.00	2066
1620	0 NEW REGULATIONS FOR CLINICAL STUDIES IN EUROPE Y.Geysels, Belgium (*)		9027.00	10627
1640	0 DISCUSSION		9030.00	10618
1640	0 THE ROLE OF THE CROS IN OPHTHALMOLOGICAL DRUG DEVELOPMENT IN EUROPE P.Elena, France (*)		9028.00	4890

1600 - 1750

Hall B

Macular Edema

Chair Baruch D. Kuppermann

030/ OR5

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 INTRAVITREAL BIOERUDIVEL SUSTAINED-RELEASE TRIAMCINOLONE MICROSPHERES SYSTEM (RETAAC): SAFETY AND PHARMACOKINETIC IN THE RABBIT EYE AND A PRELIMINARY REPORT OF ITS POTENTIAL USEFULNESS FOR THE TREATMENT DIABETIC MACULAR EDEMA J.Cardillo, Brazil (*) ; F.Paganelli, Brazil ; R.Costa, Brazil ; A.Silva, Brazil ; A.Oliveira, Brazil ; A.Lima-Filho, Brazil ; R.Belfort Jr, Brazil ; B.Kuppermann, USA		1060.00	10796
1609	0 THE HELICAL COIL DRUG TECHNOLOGY FOR DME E.De Juan, USA (*)		9046.00	4589
1618	0 DENUFOSOL TETRASODIUM FOR UVEITIC AND POST CATARACT MACULAR EDEMA C.Foster, USA (*)		9047.00	5352
1627	0 MACUGEN FOR DME J.Mones, Spain (*)		9048.00	8419
1636	0 FA IMPLANT UVEITIS C.Pavesio, UK (*)		9049.00	8767

Thursday 30 March

1600 - 1750

Hall B

Macular Edema

Chair Baruch D. Kuppermann

030/ OR5

Time	Title	Poster Board Number	Abstract Number	Reference I
1645	0 RANIBIZUMAB (LUCENTISTM) LIQUID FORMULATION PLUS SAME-DAY VERTEPORFIN PDT IS ASSOCIATED WITH A LOWER INCIDENCE OF OCULAR ADVERSE EVENTS THAN SEQUENTIAL USE OF VERTEPORFIN-PDT AND LYOPHILIZED RANIBIZUMAB U.Schmidt-Erfurth, Austria (*) ; T.Hohman, USA ; .The ANCHOR Study Group, Austria ; .The PROTECT Study Group, Austria		1140.00	9330
1650	0 SAFETY AND EFFICACY OF AN INTRAVITREAL DEXAMETHASONE BIODEGRADABLE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF PERSISTENT MACULAR EDEMA G.Williams, USA (*) ; B.Kuppermann, USA ; J.Haller, USA ; M.Blumenkranz, USA ; C.Chou, USA ; S.Whitcup, USA		1129.00	10114
1703	0 INTRAVITREAL TRIAMCINOLONE FOR MACULAR DISEASES (DME, CRVO, BRVO) I.Scott, USA (*)		1172.00	9368
1712	0 PHARMACOLOGIC RATIONALE FOR INTRAVITREAL CORTICOSTEROIDS IN RETINAL VASCULAR DISEASE J.Edelman, USA (*)		1189.00	11053
1721	0 SAFETY PROFILE OF CORTICOSTEROIDS ON RETINAL CELLS IN VITRO B.Kuppermann, USA (*) ; R.Narayanan ; S.Luthra ; L.Marques ; A.Neekhra ; M.Kenney		1044.00	7538
1730	0 INTRAVITREAL INJECTION: TECHNIQUE FOR THE SCORE AND DRCRNET STUDIES I.Scott, USA (*)		1173.00	9368
1739	0 FA IMPLANT DIABETES A.Pearson, USA (*)		9050.00	11094
1748	0 DISCUSSION		9456.00	10618

1645 - 1730

Hall A

Ocular Microbiology - advances in diagnosis and therapy of ocular viral diseases

Chair Irina Barequet

035/ OR6

Time	Title	Poster Board Number	Abstract Number	Reference I
1645	0 INTRODUCTION I.Barequet, Israel (*)		9845.00	3116
1648	0 DIAGNOSING OCULAR VIRAL INFECTIONS: PRESENT AND FUTURE R.Kowalski, USA (*)		9649.00	7329
1702	0 OVERVIEW OF ANTIVIRAL AGENTS IN THE TREATMENT OF VIRUS INFECTIONS OF THE EYE E.De Clercq, Belgium (*)		9031.00	4585
1716	0 ADVANCES IN OCULAR ANTIVIRAL DEVELOPMENT E.Romanowski, USA (*)		1149.00	10571
1725	0 DISCUSSION		9033.00	10618

Friday 31 March**0730 - 0900****Hall B*****Mini Course: Addressing Challenging Cases in Corneal Disorders****Chair* Manfred Zierhut

050/ OR25

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	0 HSV KERATITIS M.Zaal, The Netherlands (*)		9756.00	11079
0800	0 CORNEA AND SYSTEMIC DISORDERS R.Neumann, Israel (*)		9786.00	8555
0830	0 BULLOUS DERMATITIS AND EYE INVOLVEMENT M.Zierhut, Germany (*)		9736.00	10237

0900 - 0945**Hall A*****High Throughput Screening Of Neuroprotective Therapies****Chair* Leonard Levin
Wolf Lagreze

055/ OR9

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 SCREENING OF NEUROPROTECTIVE DRUGS W.Lagreze, Germany (*)		9070.00	7615
0915	0 SCREENING SYNTHETIC STEROIDS FOR NEUROPROTECTION OF RETINAL GANGLION CELLS IN GLAUCOMA N.Agarwal, USA (*) ; D.Kumar, USA ; Z.Cai, USA ; D.Covey, USA ; L.Prokai, USA ; K.Prokai, USA ; J.Simpkins, USA		1136.00	2308
0930	0 DIFFERENTIATED RGC-5 CELLS AS A MODEL FOR SCREENING RETINAL GANGLION CELL NEUROPROTECTIVE THERAPIES L.Levin, USA (*)		1162.00	11020

0900 - 0945**Hall B*****Ocular Toxicology****Chair* Frederick Fraunfelder

060/ OR10

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 DRUG-INDUCED OCULAR SIDE EFFECTS OF CLINICAL IMPORTANCE F.Fraunfelder, USA (*)		1135.00	10371
0915	0 OCULAR ELECTROPHYSIOLOGY IN MULTICENTRE TRIALS: HOW TO MEET THIS CHALLENGE? E.Zrenner, Germany (*)		1036.00	10640
0930	0 WHAT ARE THE PREFERRED OCULAR TESTS FOR HUMAN OCULAR TOXICOLOGY? W.Chambers, USA (*)		9217.00	4009

Friday 31 March

0945 - 1030

Hall A

NPDR / PDR / Neuroprotection

Chair Baruch D. Kuppermann

065/ OR11

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 OCTREOTIDE FOR DIABETIC RETINOPATHY D.Boyer, USA (*)		9670.00	2879
0955	0 EFFICACY AND SAFETY OF VITRASE(TM)-FINAL ANALYSIS E.Thomas, USA (*) ; B.Kuppermann, USA		1202.00	9792
1005	0 RUBOXISTAURIN FOR NPDR AND DME B.Kuppermann, USA (*)		9677.00	7538
1015	0 RETINAL NEUROPROTECTION A.Brucker, USA (*)		9705.00	1671
1025	0 DISCUSSION		9081.00	10618
1030	0 COFFEE BREAK		9003.00	10618

0945 - 1030

Hall B

Optimizing Glaucoma Management: Implications Of Intraocular Pressure And Ocular Blood Flow***Merck Sponsored Symposium***

Chair Jost B. Jonas

070/ OR12

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 WELCOME AND INTRODUCTION J.Jonas, Germany (*)		9950.00	7156
0950	0 SHORT-TERM VERSUS MID-TERM 24-HOUR IOP EFFICACY COMPARISON BETWEEN LATANOPROST AND THE DORZOLAMIDE/TIMOLOL MALEATE FIXED COMBINATION A.Konstas, Greece (*)		1177.00	7480
1000	0 THE ROLE OF ALTERED HEMODYNAMICS IN OCULAR PHYSIOPATHOLOGY L.Schmetterer, Austria (*)		1194.00	9326
1010	0 PATHOGENESIS OF GLAUCOMA: IMPLICATIONS OF IOP AND OBF A.Harris, USA (*)		1171.00	6650
1020	0 PANEL DISCUSSION MODERATOR: J. JONAS, GERMANY		9556.00	10618
1030	0 COFFEE BREAK		9004.00	10618

Friday 31 March

1100 - 1145

Hall A

Ocular Toxicology Of Topical Agents

Chair Penny A. Asbell

075/ OR13

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	0 TOXICITY OF OCULAR PRESERVATIVES ON THE OCULAR SURFACE P.Asbell, USA (*) ; S.Epstein ; M.Ahdoot ; C.Reddy ; K.Yee ; E.Marcus		1170.00	2399
1110	0 DRUG-INDUCED OCULAR SURFACE REACTIONS: PRESERVING THE EYEDROPS OR THE OCULAR SURFACE? C.Baudouin, France (*)		1103.00	3150
1120	0 THE EFFECTS OF PRESERVATIVES AND ANTI-GLAUCOMA DRUGS ON THE CORNEAL EPITHELIAL MIGRATION AND WOUND HEALING T.Nishida, Japan (*)		9080.00	10631
1130	0 THYROID HORMONE INFLUENCE IN THE LACRIMAL GLAND AND OCULAR SURFACE E.Rocha, Brazil (*) ; A.Dias, Brazil ; C.Módulo, Brazil ; A.Braz, Brazil ; A.Jordão Jr., Brazil ; R.Bertazzoli Filho, Brazil ; J.Marchini, Brazil		1185.00	10842
1140	0 PANEL DISCUSSION		9784.00	10618

1100 - 1145

Hall B

Changing Perspectives In Neovascular AMD Treatment***Pfizer Sponsored Symposium***

Chair

080/ OR14

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	0 AETIOLOGY OF WET AMD: ROLE OF VEGF S.Grisanti, Germany (*)		9856.00	5770
1115	0 PRINCIPLES OF ANTI-VEGF APTAMER THERAPY S.Grisanti, Germany (*)		9896.00	5770
1130	0 CLINICAL TRIAL RESULTS J.Mones, Spain (*)		9785.00	8419

1145 - 1230

Hall A

Antioxidants

Chair Paul S. Bernstein

Akihiro Ohira

085/ OR15

Time	Title	Poster Board Number	Abstract Number	Reference I
1145	0 BIOCHEMISTRY AND BIOPHYSICS OF LIPOFUSCIN AND THE MACULAR CAROTENOIDS IN AGE-RELATED MACULAR DEGENERATION: NEW INSIGHTS INTO AN OLD-AGE DISEASE P.Bernstein, USA (*) ; P.Bhosale ; B.Serban		1118.00	10820
1155	0 MEASUREMENTS OF MACULAR CAROTENOID PIGMENTS BY RESONANCE RAMAN SPECTROSCOPY IN JAPANESE A.OHIRA, Japan (*) ; A.OBANA, Japan ; Y.Gohto, Japan ; Y.Nagase, Japan ; T.Hiramitsu, Japan ; T.Hirano, Japan ; Y.Hotta, Japan ; K.Iseki, Japan ; S.Mizuno, Japan ; H.Fujii, Japan ; M.Usui, Japan ; P.Bernstein, Japan		1027.00	8639
1205	0 PHOTOPROTECTIVE AND ANTIOXIDANT PROPERTIES OF MACULAR PIGMENTS M.Wrona, Poland ; M.Rozanowska, Poland ; A.Pawlak, Poland ; T.Sarna, Poland (*)		1128.00	10633
1215	0 PHOTOOXIDATION OF A2-PE, A PHOTORECEPTOR OUTER SEGMENT FLUOROPHORE, AND PROTECTION BY LUTEIN AND ZEAXANTHIN		1010.00	10584

Friday 31 March

1145 - 1230

Hall A

AntioxidantsChair Paul S. Bernstein
Akihiro Ohira

085/ OR15

Time	Title	Poster Board Number	Abstract Number	Reference I
1225	0 DISCUSSION J.Sparrow, USA (*) ; S.Kim, USA ; K.Nakanishi, USA ; J.Zhou, USA ; Y.Itagaki, USA			10618
			9090.00	
1230	0 LUNCH BREAK			10618
			9005.00	

1145 - 1230

Hall B

**Retisert: Fluocinolone Acetonide Intravitreal Implant
Bausch & Lomb Sponsored Session**

Chair Baruch D. Kuppermann

090/ OR16

Time	Title	Poster Board Number	Abstract Number	Reference I
1145	0 NON INFECTIOUS POSTERIOR UVEITIS: EPIDEMIOLOGY AND CLASSIFICATION OF UVEITIS M.Zierhut, Germany (*)		1023.00	10237
1153	0 NON INFECTIOUS POSTERIOR UVEITIS: ADVANCES IN DIAGNOSIS OF UVEITIS B.Bodaghi, France (*)		1074.00	2781
1201	0 CLINICAL TRIALS: 2 YEAR FOLLOW UP: USA G.Jaffe, USA (*)		9810.00	7116
1209	0 A MULTICENTRE, RANDOMISED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AN INTRAVITREAL FLUOCINOLONE ACETONIDE (FA) IMPLANT COMPARED TO STANDARDISED THERAPY IN PATIENTS WITH NON INFECTIOUS POSTERIOR UVEITIS C.Pavesio, UK (*) ; B.Levy, USA ; C.Richard, France ; K.Bairi, France ; T.Comstock, USA		1220.00	8767
1217	0 DIABETIC MACULAR EDEMA RETISERT: 2 YEAR FOLLOW UP D.Elliot, USA (*)		9830.00	11075
1225	0 DISCUSSION		9788.00	10618
1230	0 LUNCH BREAK			10618
			9006.00	

1400 - 1445

Hall A

From Basic Science To Clinical Practice

Chair Hanna Levkovitch-Verbin

100/ OR17

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 GENE THERAPY FOR GLAUCOMA P.Kaufman, USA (*)		1088.00	7382
1410	0 CILIARY BODY PROGENITOR CELLS H.Quigley, USA (*)		1146.00	8897
1420	0 ENDOGENOUS NEUROPROTECTION - HOPW RETINAL GANGLION CELLS PROTECT THEMSELVES H.Levkovitch-Verbin, Israel (*)		9094.00	7578
1430	0 THE OPTIC NERVE HEAD - STRUCTURE AND SUSCEPTIBILITY FOR PROGRESSIVE DAMAGE J.Jonas, Germany (*)		9096.00	7156

Friday 31 March

1400 - 1445

Hall A

From Basic Science To Clinical Practice

Chair Hanna Levkovitch-Verbin

100/ OR17

Time	Title	Poster Board Number	Abstract Number	Reference I
1440	0 DISCUSSION			10618
			9097.00	

1400 - 1445

Hall B

Efficacy And Safety Of VEGF-A Inhibition Using A Humanized Antibody Fragment In The Treatment Of Neovascular AMD***Novartis Sponsored Symposium***

Chair Michael Larsen

105/ Reference I OR18

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 WELCOME AND INTRODUCTION M.Larsen (*)		9840.00	11016
1405	0 RANIBIZUMAB (LUCENTISTM) IMPROVES PATIENT-REPORTED OUTCOMES IN THE PHASE III MARINA TRIAL OF MINIMALLY CLASSIC OR OCCULT SUBFOVEAL CHOROIDAL NEOVASCULARIZATION, AS ASSESSED USING THE VALIDATED NATIONAL EYE INSTITUTE VISUAL FUNCTIONING (VFQ-25) QUESTIONNAIRE Y.Yang (*)		1154.00	11018
1415	0 OVERALL SAFETY RESULTS FROM TWO PHASE III PIVOTAL STUDIES OF RANIBIZUMAB IN PREVENTING VISION LOSS ASSOCIATED WITH SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION D.Pauleikhoff (*)		1153.00	11017
1425	0 SUBGROUP RESULTS FROM THE MARINA STUDY: A RANDOMIZED, CONTROLLED PHASE III STUDY OF RANIBIZUMAB (LUCENTISTM) FOR MINIMALLY CLASSIC OR OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION M.Larsen (*)		1152.00	11016
1435	0 DISCUSSION		9860.00	10618

1445 - 1530

Hall A

Exudative AMD

Chair Baruch D. Kuppermann

110/ OR19

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	0 CAND5 SIRNA FOR CNV / AMD B.Kuppermann, USA (*)		9100.00	7538
1455	0 A DOUBLE-MASKED, PLACEBO-CONTROLLED, DOSE ESCALATION, PHASE I STUDY OF INTRAVENOUS VEGF TRAP IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Q.Nguyen, USA (*) ; S.Shah, USA ; G.Hafiz, USA ; E.Holz, USA ; M.Benz, USA ; R.Rosen, USA ; J.Haller, USA ; S.Tatlipinar, USA ; K.Chu, USA ; J.Buskey, USA ; E.Furfine, USA ; D.Nadler, USA ; J.Cedarbaum, USA ; P.Campocharo, USA		1150.00	11014
1505	0 COMPARISON OF EARLY RESPONSE TO SYSTEMIC OR INTRAVITREAL BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH NEOVASCULAR AMD S.Michels, Austria (*) ; P.Rosenfeld, USA ; W.Geitzenauer, Austria ; F.Prager, Austria ; U.Schmidt-Erfurth, Austria		1123.00	8371
1515	0 TREATMENT OF CHOROIDAL NEOVASCULARIZATION WITH PEGAPTANIB J.Monés, Spain (*)		1213.00	11067

Friday 31 March**1445 - 1530****Hall A*****Exudative AMD***

Chair Baruch D. Kuppermann

110/ OR19

Time	Title	Poster Board Number	Abstract Number	Reference I
1525	0 THE VEGF TRAP FOR THE TREATMENT OF AMD Q.Nguyen, USA (*)		9105.00	11014
1530	0 COFFEE BREAK		9007.00	10618

1445 - 1530**Hall B*****Free Papers***

Chair

115/ OR20

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	0 FREE PAPERS		9880.00	10618
1530	0 COFFEE BREAK		9008.00	10618

1600 - 1730**Hall A*****Exudative AMD Continued***

Chair Baruch D. Kuppermann

120/ OR21

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 SQUALAMINE LACTATE FOR THE TREATMENT OF EXUDATIVE MACULAR DEGENERATION E.Thomas, USA (*)		1221.00	9792
1610	0 ADPEDF TREATMENT OF EXUDATIVE AMD J.Stout, USA (*) ; .AdPEDF Study Group, USA		1134.00	10370
1620	0 A NOVEL FIRST-IN-CLASS, NON-INVASIVELY DELIVERED, MULTI-TARGETED (VEGFR2/SRC/PDGFR) KINASE INHIBITOR FOR THE TREATMENT OF AMD, PDR AND DME S.Yee, USA (*) ; P.Campochiaro, USA ; L.Dellamary, USA ; M.Friedlander, USA ; G.Noronha, USA ; J.Hood, USA ; L.Schepcke, USA ; N.Umeda, USA ; B.Tam, USA ; R.Soll, USA		1113.00	10634
1630	0 SIRNA FOR CNV / AMD P.Kaiser, USA (*)		9107.00	11054
1640	0 ANTI INTEGRIN ANTIBODY FOR CHOROIDAL NEOVASCULARIZATION J.Heier, USA (*)		9109.00	6678
1650	0 IMMUNITY AND ANGIOGENEIS T.Tba (*)		9111.00	10618
1650	0 THE SCIENCE OF VEGF AND ITS IMPLICATIONS FOR THE TREATMENT OF AMD B.Katz, USA (*)		1211.00	11021
1700	0 LUCENTIS FOR CNV / AMD U.Schmidt-Erfurth, Austria (*)		9200.00	9330
1710	0 RETAANE FOR CNV / AMD P.Kaiser, USA (*)		9201.00	11054

Friday 31 March**1600 - 1730****Hall A*****Exudative AMD Continued***

Chair Baruch D. Kuppermann

120/ OR21

Time	Title	Poster Board Number	Abstract Number	Reference I
1720	0 ANGIOSYN CLASS OF MOLECULES FOR RETINA DISEASES M.Friedlander, USA (*)		9543.00	5375

1600 - 1645**Hall B*****Novel Mechanisms For Pharmacological Inhibition Of Neuronal Death***Chair Wolf Lagreze
Leonard Levin

125/ OR22

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 NEUROPROTECTION RELATED TO MAINTAINING MITOCHONDRIAL FUNCTION N.Osborne, UK (*)		9804.00	8676
1610	0 GENE THERAPY AND PROTEIN-TRANSDUCTION APPROACHES FOR NEUROPROTECTION M.Baehr, Germany (*)		9809.00	3073
1620	0 NEURONAL REGENERATION: WHAT CAN WE LEARN FROM THE SPINAL CORD? I.Maier, Switzerland (*) ; M.Schwab		1187.00	11052
1630	0 NOVEL MECHANISMS FOR THE PHARMACOLOGICAL INHIBITION OF AXONALLY-MEDIATED NEURONAL DEATH K.Martin, UK (*)		1132.00	10582
1640	0 DISCUSSION		9888.00	10618

1645 - 1730**Hall B*****In Vitro Approaches To Ocular Diseases & Drug Discovery***

Chair Neeraj Agarwal

135/ OR23

Time	Title	Poster Board Number	Abstract Number	Reference I
1645	0 STRATEGIES OF NEUROPROTECTION IN GLAUCOMA N.Agarwal, USA (*) ; D.Kumar		1223.00	2308
1655	0 THE ROLE OF CAMKII IN CELL DEATH AND SURVIVAL PATHWAYS OF RGC-5 CELLS N.Cooper, USA (*) ; X.Li ; A.Khalyfa ; W.Fan		1026.00	3793
1705	0 IN VITRO ASSAYS - FROM SCREENS TO GENES: ROLE IN OCULAR DRUG DISCOVERY G.Prasanna, USA (*)		1106.00	1704
1715	0 AQUAPORIN WATER CHANNELS: A PROMISING TARGET FOR DRUG DEVELOPMENT R.Patil, USA (*)		1174.00	11040
1725	0 OPTIC NERVE ASTROCYTES: A MODEL FOR CELL SIGNALING AND DRUG TARGETS FOR GLAUCOMA T.Yorio, USA (*) ; A.Dibas ; S.He ; R.Krishnamoorthy		1161.00	1719

Saturday 1 April**0730 - 0900****Hall A*****Mini Course: Addressing Challenging Cases in Uveal Inflammation****Chair* Manfred Zierhut

140/ OR39

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	0 TALK FOR UVEAL INFLAMMATION MINI COURSE M.De Smet, The Netherlands (*)		9337.00	4596
0800	0 TALK FOR UVEAL INFLAMMATION MINI COURSE C.Pavesio, UK (*)		9665.00	8767
0830	0 TALK FOR UVEAL INFLAMMATION MINI COURSE M.Zierhut, Germany (*)		9336.00	10237

0730 - 0900**Hall B*****Mini Course: Addressing Challenging Cases in Retinal Diseases****Chair* Salvatore Grisanti

145/ OR24

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	0 TALK FOR MINI COURSE RETINAL DISORDERS F.Geliksen, Germany (*)		9900.00	11076
0800	0 TALK FOR MINI COURSE RETINAL DISORDERS S.Grisanti, Germany (*)		9901.00	5770
0830	0 TALK FOR MINI COURSE RETINAL DISORDERS J.Wachtlin, Germany (*)		9905.00	10831

0900 - 0945**Hall A*****New Approaches To Treatment Of CNV / AMD: New PDT And Combination Therapy****Chair* Baruch D. Kuppermann

150/ OR26

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 INDOCYANINE GREEN MEDIATED PHOTOTHROMBOSIS (I-MP) FOR THE TREATMENT OF WET AMD J.Cardillo, Brazil (*)		1156.00	10796
0910	0 PHOTREX FOR AMD-UPDATE 2006 E.Thomas, USA (*) ; B.Kuppermann, USA ; J.Hill, USA ; W.Snyder, USA		1199.00	9792
0920	0 TRIAMCINOLONE + PDT FOR THE TREATMENT OF NEOVASCULAR AMD U.Schmidt-Erfurth, Austria (*)		9903.00	9330
0930	0 COMBINATION THERAPY FOR CNV / AMD (MACUGEN + TA, MACUGEN + PDT) S.Grisanti, Germany (*)		9980.00	5770
0940	0 DISCUSSION		9876.00	10618

Saturday 1 April

0900 - 0945

Hall B

New Treatments In Dry Eye

Chair Penny A. Asbell

155/ OR27

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 NERVE GROWTH FACTOR FOR DRY EYE S.Bonini, Italy (*)		9765.00	3286
0910	0 INFLAMMATION, IMMUNITY, AND DRY EYES R.Dana, USA (*)		1138.00	4224
0920	0 NEW TREATMENTS M.Rolando, USA (*)		9878.00	10635
0930	0 NEW TREATMENTS IN DRY EYE S.Kinoshita, Japan (*)		9767.00	7314
0940	0 PANEL DISCUSSION		9869.00	10618

0945 - 1030

Hall A

Vitreolytics / PVR

Chair Baruch D. Kuppermann

160/ OR28

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 MICROPLASMIN M.De Smet, The Netherlands (*)		9777.00	4596
1000	0 VIT100 FOR PROLIFERATIVE VITREORETINOPATHY N.Mandava, USA (*) ; W.Schiff, USA		1141.00	7918
1015	0 AUTOLOGOUS PLASMIN FOR ALL THAT AILS YOU G.Williams, USA (*)		9868.00	10114
1030	0 COFFEE BREAK		9009.00	10618

0945 - 1030

Hall B

*New Developments Of Therapeutic Modalities Against Ocular Refractory Diseases**Senju Sponsored Symposium*Chair Hidetoshi Yamashita
Hideyuki Sakaki

165/ OR29

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 OCULAR SURFACE RECONSTRUCTION USING TISSUE ENGINEERING TECHNIQUE S.Kinoshita, Japan (*)		1028.00	7314
1005	0 SURGICAL ADJUVANT FOR VISUALIZING VITREOUS BODY T.Sakamoto, Japan (*) ; K.Matsuhisa		1014.00	9129
1025	0 DISCUSSION		9084.00	10618
1030	0 COFFEE BREAK		9010.00	10618

Saturday 1 April

1100 - 1230

Hall A

Ocular Inflammatory Diseases

Chair Stephen C. Foster

170/ OR30

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	0 INTRODUCTION R.Neumann, Israel (*)		9603.00	8555
1102	0 EPIDEMIOLOGY – PREVALENCE OF BLINDNESS J.Kempen, USA (*)		1180.00	10823
1110	0 SURVEY OF OPHTHALMOGY DEPARTMENTS FOR PRESENCE OR ABSENCE OF AN OCULAR IMMUNOLOGIST C.Samson, USA (*)		9605.00	2082
1118	0 SURVEY OF OPHTHALMOLOGISTS FOR ATTITIDES ON THE MATTER OF IMT AS A THERAPEUTIC OPTION C.Samson, USA (*)		9608.00	2082
1126	0 GENERALLY ACCEPTED INITIAL UVEITIS SPECIALIST APPROACH: ANTERIOR UVEITIS M.Sainz De La Maza, Spain (*)		9612.00	9258
1134	0 GENERALLY ACCEPTED INITIAL UVEITIS SPEACIALIST APPROACH: INTERMEDIATE UVEITIS W.Power, Ireland (*)		1112.00	10817
1142	0 GENERALLY ACCEPTED INITIAL UVERITIS SPECIALIST APPROACH: POSTERIOR UVEITIS M.De Smet, The Netherlands (*)		9614.00	4596
1150	0 GENERALLY ACCEPTED INITIAL UVEITIS SPEACIALIST APPROACH: NON-INFECTIOUS PANUVEITIS Q.Nguyen, USA (*) ; D.Do		1157.00	11014
1158	0 STEPLADDER ALGORITHM FOR RECURRENT OR CHRONIC UVEITIS A.Vitale, USA (*)		9630.00	9979
1206	0 EXCEPTIONS TO THE STEPLADDER APPROACH R.Neumann, Israel (*)		9615.00	8555
1214	0 SPECIAL SITUATIONS U.Pleyer, Germany (*)		9075.00	8837
1222	0 A CALL TO ACTION W.Ayliffe, UK (*)		1124.00	2429
1230	0 LUNCH BREAK		9011.00	10618

Saturday 1 April

1100 - 1230

Hall B

Verteporfin's Future Role In AMD Therapy

Chair Ursula Schmidt-Erfurth

175/ OR31

Time	Title	Poster Board Number	Abstract Number	Reference I
1100	0 WELCOME U.Schmidt-Erfurth, Austria (*)		9778.00	9330
1105	0 EVOLVING STRATEGIES IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION U.Schmidt-Erfurth, Austria (*)		1190.00	9330
1125	0 RATIONALE FOR COMBINATION THERAPY P.Kaiser, USA (*)		1192.00	11054
1150	0 VERTEPORFIN IN COMBINATION WITH RANIBIZUMAB D.Pauleikhoff, Germany (*)		1191.00	11017
1205	0 PANEL DISCUSSION: EVOLVING TREATMENT GUIDELINES		9340.00	10618
1220	0 QUESTIONS AND ANSWERS		9341.00	10618
1230	0 LUNCH BREAK		9012.00	10618

1400 - 1445

Hall A

Improving IOP Control

Chair Hanna Levkovitch-Verbin

195/ OR32

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 MEDICAL AND SURGICAL METHODS TO IMPROVE UVEO-SCLERAL OUTFLOW IN GLAUCOMA S.Melamed, Israel (*) ; G.Simon, Spain ; M.Goldenfeld, Israel		1147.00	7853
1410	0 DO PATIENTS TAKE THEIR EYEDROPS? H.Quigley, USA (*)		1145.00	8897
1420	0 TRANSLATING RISK FACTORS FOR PROGRESSION INTO CLINICAL PRACTICE H.Levkovitch-Verbin, Israel (*)		9440.00	7578
1430	0 EXFOLIATIVE GLAUCOMA- HOW TO IMPROVE PROGNOSIS A.Konstas, Greece (*)		1176.00	7480
1440	0 DISCUSSION		9103.00	10618

Saturday 1 April**1400 - 1445****Hall B***Free Papers*

Chair

200/ OR33

Time	Title	Poster Board Number	Abstract Number	Reference I
1400	0 FREE PAPERS			10618
			9445.00	

1445 - 1530**Hall A***Common Glaucoma Debates*

Chair Hanna Levkovitch-Verbin

205/ OR34

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	0 EVIDENCE-BASED MANAGEMENT OF CO-EXISTING GLAUCOMA AND CATARACT D.Friedman, USA (*) ; H.Jampel, USA ; H.Quigley, USA ; N.Congdon, USA ; K.Robinson, USA ; H.Levkovitch-Verbin, Israel ; E.Bass, Israel		1041.00	11044
1500	0 THE MYTH OF LOW TENSION GLAUCOMA H.Quigley, USA (*)		1144.00	8897
1515	0 THE ROLE OF CYCLOPHOTOCOAGULATION IN GLAUCOMA THERAPY K.Martin, UK (*)		1133.00	10582
1530	0 COFFEE BREAK			10618
			9013.00	

1445 - 1530**Hall B***Free Papers*

Chair

210/ OR35

Time	Title	Poster Board Number	Abstract Number	Reference I
1445	0 FREE PAPERS			10618
			9333.00	
1530	0 COFFEE BREAK			10618
			9014.00	

1600 - 1730**Hall A***Considerations For Drug Delivery To The Posterior Segment Of The Eyes*

Chair Diane Tang-Liu

215/ OR36

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 IBMX BIOMARKER FOR BIOCOMPATIBILITY WITH RAT RETINA ROD CELLS A.Koskelainen, Finland (*)		9350.00	11078
1615	0 INTERACTION OF FACTORS CONTROLLING NEOVASCULARIZATION AND VASCULAR PERMEABILITY IN THE EYE S.Vinores, USA (*)		1072.00	10801
1630	0 INTRAVITREAL DELIVERY OF LUCENTIS (RANIBIZUMAB) AND CHALLENGES IN DOSE SELECTION J.Gaudreault, Switzerland (*)		1214.00	5885
1645	0 DEVELOPMENT OF ENCAPSULATED CELL TECHNOLOGY FOR RETINAL DEGENERATIVE DISEASES W.Tao, USA (*)		1210.00	10826
1700	0 BIOERUDIVEL SUSTAINED-RELEASE SYSTEMS: CHANGING CONCEPTS AND PARADIGMS IN TARGETING EYE DISEASES J.Cardillo, Brazil (*)		1155.00	10796

Saturday 1 April

1600 - 1730

Hall A

Considerations For Drug Delivery To The Posterior Segment Of The Eyes

Chair Diane Tang-Liu

215/ OR36

Time	Title	Poster Board Number	Abstract Number	Reference I
1715	0 OVERCOMING CHALLENGES TO POSTERIOR DRUG DELIVERY J.Lin, USA (*)		9567.00	11071

1600 - 1645

Hall B

Imaging Technologies As End Points

Chair Sara Krupsky

220/ OR37

Time	Title	Poster Board Number	Abstract Number	Reference I
1600	0 DISCUSSION: ANATOMIC VERSUS FUNCTIONAL END POINTS WILEY CHAMBERS, USA MARC DE SMET, THE NETHERLANDS RAN ZEIMER, USA		9689.00	10618

1645 - 1730

Hall B

Ocular Angiogenesis Inhibition - Pre-Clinical Studies

Chair Arup Das

230/ OR38

Time	Title	Poster Board Number	Abstract Number	Reference I
1645	0 INTRODUCTION A.Das, USA (*)		9656.00	4577
1650	0 VASCULAR RECONSTRUCTION WITH AUTOLOGOUS BONE MARROW CELLS FOR THE TREATMENT OF RETINAL VASCULAR DISEASES M.Friedlander, USA (*)		1033.00	5375
1700	0 SOMATOSTATIN ANALOGS IN ANGIOGENESIS INHIBITION M.Grant, USA (*) ; S.Jurczyk, USA ; S.Palii, USA ; S.Caballero, USA ; R.Mames, USA ; G.Shapiro, USA		1125.00	5979
1710	0 INHIBITION OF OCULAR ANGIOGENESIS BY MODULATION OF THE EPHRIN-B2/EPHB4 PATHWAY S.He, USA ; V.Krasnoperov, USA ; S.Zozulya, USA ; P.Gill, USA ; D.Hinton, USA (*)		1131.00	6708
1720	0 TARGETING PROSTAGLANDINS BOTH UPSTREAM AND DOWNSTREAM OF VEGF RECEPTOR ACTIVATION J.Penn, USA (*) ; G.McCollum ; Q.Song		1122.00	10822

Sunday 2 April**0730 - 0900****Hall A*****Mini Course: Addressing Challenging Cases in Glaucoma****Chair* Norbert Pfeiffer

235/ OR8

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	0 TALK FOR MINI COURSES GLAUCOMA N.Pfeiffer, Germany (*)		9210.00	8810
0800	0 TALK FOR MINI COURSES GLAUCOMA H.Thieme, Germany (*)		9211.00	10514
0830	0 INFLAMMATORY GLAUCOMAS M.Zierhut, Germany (*)		9215.00	10237

0730 - 0900**Hall B*****Mini Course: Addressing Challenging Cases in External Eye Diseases****Chair* Christoph M.E. Deuter

237/ OR7

Time	Title	Poster Board Number	Abstract Number	Reference I
0730	0 DRY EYE DISEASE: DRUG RELATED PROBLEMS C.Baudouin, France (*)		9205.00	3150
0800	0 SEVERE DRY EYE (GRAFT VERSES HOST-REACTION, SJOGREN-SYNDROME ETC) M.Ronaldo, Italy (*)		9208.00	10635
0830	0 OCULAR ALLERGY C.Deuter, Germany (*)		9600.00	10301

0900 - 0945**Hall A*****Dry AMD****Chair* Baruch D. Kuppermann

240/ OR40

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 RHEOPHERESIS FOR DRY AMD: EFFICACY AND ANALYSIS OF MIRA-1 CLINICAL TRIAL D.Boyer, USA (*)		1160.00	2879
0908	0 NUTRITIONAL THERAPY FOR AMD M.Cooney, USA (*)		9566.00	4119
0916	0 GENISTEIN FOR AMD E.De Juan, USA (*)		9667.00	4589
0924	0 RETINOIDS FOR AMD E.De Juan, USA (*)		9669.00	4589
0932	0 CAN STATINS PREVENT AMD? E.Friedman, USA (*)		9865.00	1897
0940	0 DISCUSSION		9867.00	10618

Sunday 2 April

0900 - 0945

Hall B

Free Papers

Chair

245/ OR41

Time	Title	Poster Board Number	Abstract Number	Reference I
0900	0 FREE PAPERS			10618
			9345.00	

0945 - 1030

Hall A

Free Papers

Chair

250/ OR42

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 FREE PAPERS			10618
			9559.00	

0945 - 1030

Hall B

Clinical Trials In Dry Eye

Chair Penny A. Asbell

255/ OR43

Time	Title	Poster Board Number	Abstract Number	Reference I
0945	0 FLUOROPHOTOMETRY AS A DIAGNOSTIC TOOL FOR THE EVALUATION OF DRY EYE DISEASE P.Asbell, USA (*) ; M.Fahim ; S.Haji ; C.Koonapareddy		1169.00	2399
0955	0 ANIMAL MODELS OF DRY EYE S.Barbino, USA (*)		9679.00	10630
1005	0 EVALUATING NEW THERAPIES FOR PATIENTS WITH DRY EYE D.Kellerman, USA (*)		1121.00	7395
1015	0 PANEL DISCUSSION		9563.00	10618